Past, Present, and Future Challenges in Breast Cancer Treatment

Abstract S3-2: Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02):

(2014) S Aebi et al.   CANCER RESEARCH

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

(2013) Viviana Galimberti et al.   LANCET ONCOLOGY

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

(2013) A. Prat et al.   ONCOLOGIST

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) F. Cardoso et al.   ANNALS OF ONCOLOGY

The European Medicines Agency Review of Eribulin for the Treatment of Patients with Locally Advanced or Metastatic Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

(2012) E. Pean et al.   CLINICAL CANCER RESEARCH

Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays?

(2012) Debora Fumagalli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

(2012) D. Craig Allred et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

(2012) James L. Khatcheressian et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

(2012) John R Mackey et al.   LANCET ONCOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer

(2012) J. A. O'Shaughnessy et al.   ONCOLOGIST

Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis

(2011) Armando E. Giuliano   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

(2011) Andrew N. Freedman et al.   JOURNAL OF CLINICAL ONCOLOGY

High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

(2011) Donald A. Berry et al.   JOURNAL OF CLINICAL ONCOLOGY

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Exemestane for Breast-Cancer Prevention in Postmenopausal Women

(2011) Paul E. Goss et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

A review of PARP inhibitors: from bench to bedside

(2010) C. Underhill et al.   ANNALS OF ONCOLOGY

Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells

(2010) Laura B. Carpin et al.   BREAST CANCER RESEARCH AND TREATMENT

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

(2010) V. G. Vogel et al.   Cancer Prevention Research

State of the epidemiological evidence on physical activity and cancer prevention

(2010) Christine M. Friedenreich et al.   EUROPEAN JOURNAL OF CANCER

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Subtypes and the Risk of Local and Regional Relapse

(2010) K. David Voduc et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo

(2010) Rizia Bardhan et al.   NANO LETTERS

Effect of Obesity on Breast Cancer Development

(2010) M. P. Cleary et al.   VETERINARY PATHOLOGY

Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis

(2009) Ping Tang et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Prediction of Local Recurrence, Distant Metastases, and Death After Breast-Conserving Therapy in Early-Stage Invasive Breast Cancer Using a Five-Biomarker Panel

(2009) Ewan K.A. Millar et al.   JOURNAL OF CLINICAL ONCOLOGY

Increasing Rates of Contralateral Prophylactic Mastectomy Among Patients With Ductal Carcinoma In Situ

(2009) Todd M. Tuttle et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Relevance ofHER2Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer

(2009) Giuseppe Curigliano et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer

(2009) Stewart J. Anderson et al.   JOURNAL OF CLINICAL ONCOLOGY

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

(2009) Ana M. Gonzalez-Angulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Ixabepilone in Patients with Metastatic Breast Cancer with Primary Resistance to Taxanes

(2008) Denise A. Yardley   Clinical Breast Cancer

Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy

(2008) Paul L. Nguyen et al.   JOURNAL OF CLINICAL ONCOLOGY

Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group

(2008) Marianne Kyndi et al.   JOURNAL OF CLINICAL ONCOLOGY

Observation of Orbitally ExcitedBsMesons

(2008) T. Aaltonen et al.   PHYSICAL REVIEW LETTERS